Unfortunately some errors appeared in this paper.
In Table 1 , 'Potential decrease MI b ' should have appeared as an Advantage, not Disadvantage, for Thiazolidinediones (glitazones).
In Figure 1 , the footnote for 'Intensive insulin + metformin ± glitazone' should have been b not c . In the Discussion, the sentence: 'These findings have led to a stronger (black box) warning in the prescribing information for the thiazolidinediones [15]' should have read:
'These findings have led to a stronger 'black box' warning in the prescribing information for rosiglitazone regarding the risk for myocardial infarction and for both thiazolidinediones regarding the risk for CHF [15] '.
Reference 15: The website was last accessed on 17 November 2007, not 25 October 2007. Diabetologia (2008 ) 51:522 DOI 10.1007 The online version of the original article can be found at http://dx.doi. org/10.1007/s00125-007-0873-z.
